Taiwanese Anaplastic Thyroid Cancer Registry

Launched by NATIONAL HEALTH RESEARCH INSTITUTES, TAIWAN · Aug 17, 2025

Keywords

ClinConnect Summary

This clinical trial is creating a special registry to better understand a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer (ATC). Even with treatments like surgery, radiation, and chemotherapy, this cancer often comes back or gets worse. Recently, doctors have found that some patients with specific genetic changes might benefit from newer, targeted treatments. However, many patients don’t have these changes, and treatment options are very limited. This study aims to collect detailed information and tumor samples from many patients across different hospitals to learn more about the disease, identify useful biomarkers (signs in the body that can guide treatment), and find new treatment possibilities.

People who have been diagnosed with ATC since 2015 and can understand and agree to participate may be eligible. Importantly, patients who have already passed away before June 30, 2025, can also be included to help gather more data. Participants won’t be asked to undergo new treatments but will help by allowing researchers to collect their medical information and tumor samples. This study hopes to improve knowledge about ATC and lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pathologically or cytologically confirmed ATC and diagnosed after 2015.
• • 2. Capable of understanding and complying with the protocol requirements and signed informed consent. The dead patient can be enrolled without signed informed consent and they were dead before 2025.6.30.
• Exclusion Criteria:
• • 1. Inability and unwillingness to give informed consent except dead patient.
• • 2. Patients refuse for collection of clinical data and follow up.